PROCEPT BioRobotics Corporation announced that it has successfully completed the first commercial Aquablation therapy procedures in Japan. The procedures were carried out at two premier medical institutions, in association with the 100 patient post-market surveillance study. Completing the first commercial procedures in Japan represents another important milestone in PROCEPT BioRobotics’ global expansion, highlighting the growing acceptance and recognition of Aquablation therapy as a pioneering solution for BPH patients. “We view Japan as a very promising market for the adoption of Aquablation therapy, which has a long history of adopting new, innovative technologies, while prioritizing patient outcomes. Similar to our approach in the U.S., we intend to pave the way in Japan with solid clinical data and support from key opinion leaders, setting the stage for a dynamic and lasting commercial success,” said Reza Zadno, PROCEPT BioRobotics’ CEO.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PRCT:
- PROCEPT BioRobotics to Present at the 2023 Wells Fargo Healthcare Conference in Boston
- Procept BioRobotics, NorthShore University announce milestone
- Twilio upgraded, Sealed Air downgraded: Wall Street’s top analyst calls
- Procept BioRobotics initiated with an Overweight at Piper Sandler
- Procept BioRobotics 4.422M share Spot Secondary priced at $33.92